Guided Therapeutics, Inc.
GTHP
$0.1088
$0.00888.80%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -92.86% | -42.42% | -44.93% | 173.33% | 653.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -92.86% | -42.42% | -44.93% | 173.33% | 653.85% |
| Cost of Revenue | -91.94% | -85.60% | -81.82% | -38.20% | -23.46% |
| Gross Profit | -94.44% | 133.90% | 130.77% | 145.76% | 152.94% |
| SG&A Expenses | -37.26% | -76.41% | -77.74% | -45.02% | -20.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.83% | -65.90% | -69.04% | -38.47% | -15.85% |
| Operating Income | 22.37% | 66.30% | 69.41% | 40.17% | 18.46% |
| Income Before Tax | 30.73% | 56.19% | 59.25% | 35.76% | 19.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.73% | 56.19% | 59.25% | 35.76% | 19.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.73% | 56.19% | 59.25% | 35.76% | 19.65% |
| EBIT | 22.37% | 66.30% | 69.41% | 40.17% | 18.46% |
| EBITDA | 22.45% | 66.44% | 69.55% | 40.32% | 18.64% |
| EPS Basic | 39.05% | 58.96% | 63.06% | 50.83% | 53.22% |
| Normalized Basic EPS | 26.03% | 66.41% | 72.77% | 58.50% | 52.54% |
| EPS Diluted | 26.11% | 57.33% | 61.64% | 50.23% | 53.62% |
| Normalized Diluted EPS | 26.03% | 66.41% | 72.77% | 58.50% | 52.54% |
| Average Basic Shares Outstanding | 12.15% | 10.40% | 17.40% | 32.48% | 57.47% |
| Average Diluted Shares Outstanding | 12.15% | 10.40% | 17.40% | 32.48% | 57.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |